PSA levels in unaffected first degree relatives of prostate cancer patients are higher than in men without family history of the disease

10518 Background: Survival rates for childhood cancer patients have improved dramatically, but the growing survivor population suffers from increased treatment-related toxicity including high risk for cardiovascular disease (CVD). While the link between chemotherapy and radiation to cardiotoxicity is well established, few studies seek to determine if an underlying familial risk for cardiovascular disease contributes or predicts this risk. The Utah Population Database (UPDB) is a genealogical resource linked to statewide cancer diagnoses and electronic medical data in which family history is objectively determined. Methods: We calculated the risk of subsequent CVD (ICD-9 401-449) in relatives of 5602 pediatric cancer patients diagnosed at ages 0-19 in Utah from 1966-2013 with no congenital CVD-related anomalies (ICD-9 745-747, 758-759). We identified 964 patients with subsequent CVD diagnoses. Cox models provided recurrence-risk estimates in first-degree relatives of patients compared to relatives of 5:1 matched controls. Results: Pediatric cancer patients were at 5-fold risk of CVD compared to controls ( P< 10-15). In pediatric patients with subsequent CVD, first-degree relatives were at 30% increased CVD risk compared to relatives of cancer-free controls (HR = 1.31, 95%CI 1.16-1.47; P< 10-5). In pediatric patients without CVD, only parents exhibited slight CVD risk (HR = 1.08, 95%CI 1.03-1.14; P= 0.002). In 685,000 individuals with a non-congenital CVD history, pediatric cancers among their first-degree relatives were associated with a similar increased risk of subsequent CVD, compared to pediatric cancers among relatives of controls with no CVD events (HR = 1.39, 95%CI 1.18-1.64, P< 10-4). Conclusions: The UPDB is powerful for investigating comorbidities in cancer patients and their families without recall bias from self-reported family medical history. A family history of CVD may increase risk of CVD-related comorbidities among pediatric cancer patients by 30-40% beyond that observed in patients without a CVD family history. This finding suggests that in addition to a cancer family history, a CVD-related family history should be assessed in children diagnosed with cancer.

Download Full-text

BRCA2 Mutation Should be Screened Routinely and Early as a Poor Prognostic Biomarker in Prostate Cancer Patients With a Family History of Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1142 ◽

2017 ◽

Vol 99 (2) ◽

pp. E225-E226

Author(s):

M. Cui ◽

X.S. Gao ◽

X. Gu ◽

M. Ma ◽

X.Y. Li

Keyword(s):

Prostate Cancer ◽

Family History ◽

Cancer Patients ◽

Prognostic Biomarker ◽

Brca2 Mutation ◽

Family History Of Cancer ◽

History Of ◽

History Of Cancer

Download Full-text

Absence of history of oral cleft in first-degree relatives of patients with prostate cancer

Dentistry 3000 ◽

10.5195/d3000.2019.88 ◽

2019 ◽

Vol 7 (1) ◽

Cited By ~ 1

Author(s):

Cláudia De Alvarenga Diniz Fonseca ◽

Daniella Reis Barbosa Martelli ◽

Ianná Luana Freitas Almeida ◽

Galeno Hassen Sales ◽

Rodrigo Soares de Andrade ◽

...

Keyword(s):

Prostate Cancer ◽

Family History ◽

Cleft Lip ◽

Control Group ◽

Chi Square ◽

Exact Test ◽

First Degree Relatives ◽

History Of ◽

Risk Magnitude ◽

Magnitude Assessment

Objective: To evaluate the occurrence of nonsyndromic cleft lip and/or palate (NSCL/P) in families of patients with prostate cancer (PC).Study design: We conducted a case-control study involving a total of 748 individuals, 280 of which had PC, and 468 were free-cancer healthy individuals. The patients answered a questionnaire with basic demographic information and family history of NSCL/P in first-degree relatives. The information collected was stored in a database and analyzed by using the statistical program SPSS® 24.0 for Windows (Chicago, IL, USA). In order to determine the association with NSCL/P, chi-square and Fisher’s exact test and odds ratio (OR) with its 95% confidence interval (95% CI) for risk magnitude assessment. Values with p<0.05 were considered statistically significant.Results: Of total patients with PC, 2 had a positive history of NSCL/P. In the control group, 7 patients reported family history of NSCL/P (1df chi-square, p=0.34; Fisher´s exact test, p=0.49). The average age of the cases diagnosed with PC was 71.35±7.70 years, and control group was 64.42±9.67 years.Conclusion: Despite the limited population, the frequency of NSCL/P was not significantly increased in the first-degree relatives of patients with PC. Studies with larger samples and molecular analyses are needed to better understand the possible relationships in the etiology of cancer and NSCL/P.

Download Full-text

645P Prediction of BRCA2 mutations in prostate cancer patients according early onset, metastatic phenotypes or family history of breast/ovary cancer

Annals of Oncology ◽

10.1016/j.annonc.2020.08.904 ◽

2020 ◽

Vol 31 ◽

pp. S528-S529

Author(s):

G. Cancel-Tassin ◽

P. Leon ◽

V. Bourdon ◽

B. Buecher ◽

S. Oudard ◽

...

Keyword(s):

Prostate Cancer ◽

Family History ◽

Cancer Patients ◽

Early Onset ◽

Ovary Cancer ◽

History Of ◽

Brca2 Mutations

Download Full-text

Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.6_suppl.143 ◽

2021 ◽

Vol 39 (6_suppl) ◽

pp. 143-143

Author(s):

Rachel Sabol ◽

Elisa Marie Ledet ◽

Ellen Jaeger ◽

Marcus W. Moses ◽

Brian E. Lewis ◽

...

Keyword(s):

Prostate Cancer ◽

Ovarian Cancer ◽

Genetic Testing ◽

Family History ◽

Personal History ◽

Sample Collection ◽

First Degree Relatives ◽

Pathogenic Variants ◽

Damage Repair ◽

History Of

143 Background: Recent literature highlights the importance of germline genetic testing in prostate cancer (PCa) patients. Surprisingly, a literature review indicates that family history records are incomplete in published studies. Methods: Prospective and complete family history data were gathered from 496 men in a single institution with a personal history of PCa who underwent germline genetic testing using a panel of at least 79 genes (Invitae testing) from 2016-2020. Comprehensive FH were obtained in all PCa patients in this database and analysis of prevalent FH was assessed at the time of sample collection. Age, race, metastastes at any time, and Gleason score were also ascertained. MUTYH heterozygotes were not considered pathogenic. Results: Pathogenic/likely pathogenic variants (PV/LPVs) were not associated with age at diagnosis, race, or presence of metastasis. Men with Gleason scores 8-10 at time of diagnosis were more likely to have PV/LPV ( P= 0.004). One or more first degree relatives (FDR) with any cancer with was not predictive for germline PV/LPVs for men with PCa ( P= 0.96). Analysis of patients with one or more FDR with breast, prostate, ovarian, or pancreatic cancer revealed that only FDR with breast cancer ( P = 0.028) or ovarian cancer ( P = 0.015) was predictive for PV/LPVs. Though one or more FDR with prostate cancer did not predict a PV/LPV in the overall panel, further analysis indicate that a history of a FDR with PCa was predictive for PV/LPV in a DNA damage repair (DDR) gene ( P= 0.044). Conclusions: In men with a personal history of PCa, germline PV/LPVs were associated with a FDR with breast or ovarian cancer. A FDR with PCa was predictive for PV/LPV in DDR genes. These data emphasize the contribution of FH to germline genetic testing results in a cohort with complete ascertainment of cancer in first degree relatives.

Download Full-text

Germline mutations in DNA repair genes in a large series of unselected Chinese prostate cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e17523 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e17523-e17523

Author(s):

Yu Wei ◽

Yao Zhu ◽

Junlong Wu ◽

Dingwei Ye ◽

Hao Zeng ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Repair ◽

Genetic Testing ◽

Family History ◽

High Risk ◽

Cancer Patients ◽

Germline Mutations ◽

Dna Repair Genes ◽

History Of ◽

Repair Genes

e17523 Background: Germline DNA repair gene (DRG) mutations has emerged as a potential determinant of cancer risk and therapeutic response in PCa. Despite substantial advances in delineating the germline mutation in DRGs among Caucasian population, the prevalence of mutations in DRGs are largely unknown among a large series of unselected prostate cancer patients in Chinese population. Methods: We enrolled 1003 prostate cancer patients from three different hospitals in China, unselected for family history of cancer or age at diagnosis. All patients received germline genetic testing using a clinician-selected multi-gene panel. The 18 DNA repair genes and HOXB13, which has established or emerging potential clinical actionability in PCa, were analyzed in our study. Results: A total of 94 (9.7%) deleterious germline mutations were identified among the 1003 unselected prostate cancer patients. Of these, 5.6% patients carried a BRCA1 or BRCA2 mutations (5.2% in BRCA2 and 0.4% in BRCA1), 3.6% patients carried other DRG mutations (including 10 genes) and 0.5% patients carried HOXB13 mutations. Besides, variants with uncertain significance (VUS) were found in approximately 45% patients. We also divided 633 metastatic PCa patients into 542 de novo metastastic PCa and 91 recurrent metastastic PCa and found mutation frequencies did not differ between these two groups (9.0% vs 11.6%, p = 0.6). Patients with younger age of onset or family history of cancers were more likely to harbour germline mutations in DRGs. However, the rate of germline mutations were still at a high level for patients more than 70 years old (6.7%) and patients without family history of cancers (7.5%). There is no statistically significant difference in the mutation frequencies between patients with metastasis and without metastasis (7.5% vs 9.2%, p = 0.4), which may be because 85% patients without metastasis in our cohort were in high to very high risk group or have lymph node metastasis. Conclusions: To our knowledge, our study reported the largested series of Chinese PCa patients who received germline genetic testing. Our study provided a rationality for germline genetic testing criteria from high risk to metastastic PCa regardless of family history considering the high proportion. In addition, we recommended a multigene panel covering 13 genes ( ATM, BRCA1, BRCA2, CHEK2, FANCA, HOXB13, MSH2, MSH6, NBN, PALB2, RAD51C, RAD51D, TP53) in China. Nevertheless, the high prevalence of VUS (45%) in Chinese PCa patients warrant further efforts.

Download Full-text

How Valid are Patient Reports of Family History of Illness?

Methods of Information in Medicine ◽

10.1055/s-0038-1635275 ◽

1980 ◽

Vol 19 (03) ◽

pp. 162-164 ◽

Cited By ~ 1

Author(s):

Rachel Harris ◽

W. Margaret ◽

Kathleen Hunter

Keyword(s):

Family History ◽

Medical History ◽

Cancer Patients ◽

Cause Of Death ◽

Death Certificate ◽

Recall Rate ◽

Patient Reports ◽

Small Subgroup ◽

History Of ◽

Medical Histories

The recall rate of patients’ family medical histories was studied in 200 cancer and non-cancer patients. Data on age and cause of death for parents and grandparents were collected. Although most patients knew the age and cause of death of parents, less than half knew for grandparents. Cancer patients had significantly greater recall for maternally related relatives. A subsample of patients’ family medical histories was compared to death certificate data. Patients’ reports were found to be highly inaccurate. Since only a small subgroup could provide medical history data for grandparents, the generaliz-ability for history of family illness is questioned.

Download Full-text